Skip to content

Influence of Water Soluble Silicon for Fatty Liver Combined with Lifestyle Related Disease

Influence of Water Soluble Silicon for Fatty Liver Combined with Lifestyle Related Disease - Effect of water-soluble silicon for fatty liver

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031436
Enrollment
30
Registered
2018-02-23
Start date
2018-02-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lifestyle-related disease Combined fatty liver

Interventions

Approximately 9 ml of water-soluble silicon is drunk for 6 months per day. Diet therapy is also done for drinking intake group. For non-ingesting group, do not drink it but do only usual diet therapy.

Sponsors

Aichi Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who satisfy any of the following items are targeted. 1: outpatient with lifestyle-related disease 2: Patients complicated with metabolic syndrome 3: Patients complicated with nonmetabolic syndrome and judged as fatty liver by image diagnosis 4: Patients with fatty liver whose other liver injury was denied

Exclusion criteria

Exclusion criteria: Exclude any person who falls under any of the following. 1 Viral hepatitis and liver cirrhosis 2 serious liver dysfunction (liver function test value is more than 3 times normal upper limit) 3 heart failure 4 Severe ketosis or Diabetic coma Type 1 diabetes 5 severe renal dysfunction 6 Severe infection or Patients before and after surgery 7 Patients with a history of hypersensitivity to water-soluble silicon 8 Patients who may be pregnant or pregnant 9 Patients with metabolic liver disease 10 Patients with autoimmune liver disease 11 Patients with cirrhosis /due to causes other than 1 12 When the consent of the patient can not be obtained 13 Case in which the doctor approved inappropriate for participation in the study

Design outcomes

Primary

MeasureTime frame
Blood pressure measurement, physical measurement, general blood test, blood biochemical test, abdominal ultrasonography, fibrosis marker test, inflammatory marker test, oxidative stress type marker test, adipocytokine type marker test, questionnaire

Countries

Japan

Contacts

Public ContactYoshitaka Fukuzawa

Aichi Medical University Hospital Preemptive and Integrative Medicine Center

yofuku@aichi-med-u.ac.jp0561-62-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026